Sunday 11 October 2026
Export all JNJ data to Excel Powerpack
Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to June 2026, revenue grew 6.60%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
261.44
4.96
+1.93%
Follow JNJ
Johnson & Johnson (JNJ) SEC filings, changes and red flags
Red flags
-
Officer departure
Johnson & Johnson reported the departure of an officer or director
Filings
| Form | Period | Filed | What it reports | Flags |
|---|---|---|---|---|
| 8-K | Aug 4, 2026 | 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits | Officer departure | |
| 8-K | Jul 29, 2026 | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | ||
| 8-K | Jul 27, 2026 | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 28, 2026 |
P1I2: 48 added · 13 removed · 34 modified P2I1A: no comparison — the Item was not found |
||
| 8-K | Jul 15, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Apr 23, 2026 | 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits | ||
| 10-Q | Mar 29, 2026 | |||
| 8-K | Apr 14, 2026 | 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-K | Dec 28, 2025 |
1: 2 added · 4 removed · 21 modified 1A: 5 added · 10 modified 7: 27 added · 31 removed · 57 modified |
||
| 8-K | Jan 21, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Sep 28, 2025 | |||
| 8-K | Oct 14, 2025 | 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 8-K | Sep 8, 2025 | 5.02 Departure or appointment of directors or officers | ||
| 10-Q | Jun 29, 2025 | |||
| 10-K | Dec 29, 2024 |